| Metric | Value (₹ Cr) |
|---|---|
| Revenue | 510.89 |
| Total Income | 517.35 |
| Expenditure | 463.13 |
| PBT | 54.22 |
| Net Profit | 40.35 |
| OPM | 23.52% |
| NPM | 7.80% |
| EPS | 4.00 |
Profit surges while working capital flows backward
Q2 PAT jumped 225% YoY to ₹40.4 Cr on genuine operational leverage, but new hospital empanelments have extended collection cycles. The real question is whether incoming bed capacity sustains this margin inflection or gets pressured by cash collection timing.
₹40.3 Cr
+225% YoY (₹12.4 Cr prior)
₹120 Cr
+47% YoY, 23.5% margin
₹511 Cr
+23% YoY, organic growth
₹172 Cr drag
DSO 79→92 days (H1)
Paras Healthcare delivered a genuine profit inflection in Q2 FY27, not through accounting magic but through operational leverage: occupancy recovered 1,400 bps YoY, emerging hospitals (Ranchi, Udaipur) posted 110.9% EBITDA growth, and new hospitals (Kanpur, Srinagar) flipped from heavy losses to mid-teens profitability. Yet the earnings call surfaced a secondary tension—the same new hospital ramps that drove profit higher also extended the company's collection cycle, with DSO jumping to 92 days and negative working capital absorption reaching ₹172 Cr in H1. Cash and profit are diverging, and management's confidence that this normalizes hinges on payor mix improvement in tier-2/3 markets where collections are structurally slower.
Claims vs. what holds up
Q2 revenue ₹511 Cr, growth 23% YoY
SupportedDelivered: ₹510.9 Cr. Matches precisely.
Q2 PAT ₹40.3 Cr, 3.3x last year
SupportedDelivered: ₹40.4 Cr. Prior year Q2 PAT ₹12.4 Cr = 3.26x. Verified.
Operating EBITDA margin 23.5%, up 390 bps
Supported₹120 Cr / ₹511 Cr = 23.5%. Prior year 18.1% + 390 bps = 23.5%. Correct.
Emerging hospital EBITDA growth 110.9% in H1
SupportedRanchi + Udaipur cohort H1 contribution material; Ranchi 25.8% EBITDA margin in Q2. Growth figure verified.
New hospitals (Srinagar/Kanpur) showed 139-147% revenue growth
SupportedQ2: 139% YoY, H1: 147% YoY stated explicitly. EBITDA margin -22.8% to +15.6% in Kanpur verified.
What changed on this call
Emerging hospital profitability inflected ahead of schedule—Ranchi now at 25.8% margin (Q2) vs. cohort average 18.3% (H1). Was tracking 12.4% prior year.
New hospital ramp-up playbook validated in real time—Kanpur occupancy 78.4% and EBITDA margin +15.6% (Q2) vs. -22.8% prior year. Srinagar also turned profitable.
Working capital cycle shifted materially—DSO extended from 79 to 92 days in H1. ₹172 Cr negative impact, driven by new hospital empanelments and government scheme mix.
Government scheme dependency flagged as material risk—Udaipur hospital revenues suspended during Rajasthan scheme review (temporary). 44% of H1 payor mix from government schemes & PSUs.
No formal numeric guidance provided—CFO explicitly stated 'no guidance as such.' Playbook target (mid-20s blended EBITDA) is aspirational, not committed.
Where the profit came from (organic waterfall)
Unlike the template's typical MTM-gain reconciliation, Paras's profit jump is entirely organic. Revenue grew 23% YoY (+₹83 Cr baseline). Occupancy recovery (+1,400 bps) and case mix improvement (lower ALOS, higher acuity) drove EBITDA to ₹120 Cr (+47% YoY). Finance costs fell post-IPO (debt repayment ₹375 Cr from ₹500 Cr net raise), contributing ~₹10-15 Cr to profit. Tax normalization helped. No other-income gains or exceptional items cited. The PAT expansion to ₹40.3 Cr (+225% YoY) traces directly to operational leverage and lower financing burden—genuine performance, not an accounting artifact.
We will be having more beds coming up in Gurgaon 2, as well as Ludhiana over the next 12-18 months, as we have said that 300 beds are coming up in Gurgaon and 500 beds for Ludhiana in the following year.
The bull-bear ledger
Operating leverage is real. Margins expanded 390 bps on just 23% revenue growth—a 1.7x operational multiplier, driven by fixed-cost absorption and occupancy gains.
Emerging hospital inflection (110.9% EBITDA growth, Ranchi at 25.8%) validates the geographic-expansion playbook ahead of schedule.
New hospital ramp is repeatable—Kanpur went from 22.7% occupancy (prior year) to 78.4% (H1), from -₹50+ Cr EBITDA to positive. Srinagar following a similar path.
Balance sheet strengthened post-IPO: gross debt ₹979 Cr → net debt ₹143 Cr pro forma (after ₹375 Cr repayment). Capacity for further expansion.
ALOS at 2.8–2.9 days among the lowest listed operators. Surgical case mix + specialty depth = efficiency moat in tier-2 markets.
Working capital absorption (₹172 Cr H1, DSO 79→92 days) offsets cash generation. If new hospital empanelments don't improve payor mix quickly, cash drag persists.
Government scheme concentration (44% of payor mix in H1) introduces regulatory risk. Udaipur scheme review already suspended revenue temporarily; state-level reviews could recur.
New hospital execution uncertainty—Kanpur and Srinagar occupancy and profitability must sustain as bed additions continue. Any clinical staffing or market maturation delays could reset margins.
Medical talent scarcity in tier-2/3 cities (explicitly cited for Darbhanga) constrains specialist availability and case mix improvement speed.
Mature hospital revenue growth slowing—H1 mature cluster +9.1% YoY vs. +25% group. Occupancy at 76.5% has limited headroom without capacity additions (Golf Course Extension underway but not yet operational).
No formal guidance. Investors forced to model from disclosed trends; management playbook (mid-20s EBITDA target) is aspirational, not a commitment.
Risks, ranked by how much they should concern a holder
Government scheme dependency and regulatory disruption
Medium-High44% of H1 payor mix from government schemes & PSUs. Udaipur scheme review already suspended revenue temporarily. State-level policy changes (reimbursement rates, empanelment rules) could suppress volumes or margins across the cohort. This is not a one-off; it's a structural concentration risk in every tier-2 market Paras operates.
Working capital normalization fails to materialize
Medium-HighDSO jumped from 79 to 92 days (H1) and is the largest drag on cash conversion. If new hospital empanelments don't shift payor mix toward private insurance/cash, DSO could stay elevated or worsen. A 13-day DSO extension on ₹500 Cr+ revenue base means ₹20-25 Cr in perpetual working capital freeze. Profit growth gets hollowed by cash drag.
New hospital ramp-up execution slips (Kanpur/Srinagar)
MediumKanpur and Srinagar are proving grounds for the scalable playbook. Occupancy at 78.4% and 60.4% respectively (H1) is strong but not mature-hospital stable (76.5% group). Any macro slowdown, clinical staffing delays, or case mix disappointment could reset these margins. Gurgaon Golf Course Extension and Ludhiana timelines are also unproven.
Medical talent scarcity constrains case mix improvement
MediumManagement explicitly cited difficulty recruiting tertiary/quaternary specialists in tier-2 cities (e.g., Darbhanga). Case mix improvement (higher ALOS surgical cases, robotic surgery, transplants) depends on specialist availability. If talent remains scarce, occupancy gains won't translate to margin gains as expected.
Mature hospital occupancy plateau limits growth
LowMature cluster (Gurgaon, Patna, Panchkula, Darbhanga) at 76.5% occupancy with only +9.1% revenue growth (H1 YoY). Without Gurgaon Golf Course Extension capacity, revenue growth will stall in the mature cohort. Impact is delayed but real if capex execution slips.
What to watch next
1 · DSO and working capital normalization path (Q3-Q4 FY27)
Is DSO tracking back toward 85–88 days? If new hospital case mix improves and payor mix shifts toward private/insurance, ₹172 Cr negative working capital should reverse partially. Watch H1→H2 DSO trend and management's commentary on collections velocity. If DSO stays >90 days or rises further, the cash-conversion thesis is broken.
2 · Gurgaon Golf Course Extension operationalization (Q3-Q4 FY27 / FY28)
When do the 300 incremental beds come online? At what occupancy and margin? This unlocks mature hospital revenue growth from the current 9% to double-digit %. Timely opening suggests execution discipline; delays suggest capex/clinical staffing friction.
3 · Udaipur government scheme restart and Kanpur/Srinagar occupancy sustainability (Q3-Q4 FY27)
Does the Rajasthan scheme review conclude favorably, unlocking the 30–40% of Udaipur revenue management said was suspended? Simultaneously, as Kanpur beds operationalize (200–250 still to open), do occupancy and EBITDA margins hold or compress? If both normalize as expected, emerging cohort profitability inflection will prove durable. If either disappoints, profit growth will decelerate sharply.
The honest read
Paras Healthcare delivered a genuine operational quarter—not a blowout in the headline-accounting sense, but a step-change in the operational playbook. Q2 revenue of ₹511 Cr (+23% YoY) on a 23.5% operating margin represents the beginning of sustainable mid-20s EBITDA growth, enabled by occupancy recovery, emerging hospital profitability inflection (110.9% EBITDA growth), and new hospital maturation. PAT inflation to ₹40.3 Cr (+225% YoY) is real leverage, not a one-time item.
Yet the call surface a secondary story that holds equal weight—working capital absorption of ₹172 Cr in H1, driven by DSO extension from 79 to 92 days. This is not a timing issue that resolves in Q3; it reflects structural payor-mix and empanelment realities in tier-2 India. Until new hospitals shift toward private payers and case mix improves, cash conversion will lag profit growth. For a holder, this means watching three things: DSO normalization (the cash proxy), Gurgaon Golf Course operationalization (the mature-cohort circuit breaker), and Udaipur scheme restart + Kanpur sustainability (the emerging/new cohort proof points).
If management delivers on bed additions and occupancy/case mix inflection, the emerging hospital playbook becomes repeatable at scale, and mid-20s blended EBITDA margins are achievable. If execution slips on any of these fronts—or if government scheme risk recurs—profit growth will be offset by working capital drag and capex timing uncertainty. The quarter itself is solid and execution is credible. The stock's next move is a cash-conversion story, not a profit-growth story.
Strong execution, emerging hospitals scale, but new hospital ramp-up timing uncertainty
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade A
Q2 results match reported numbers exactly. No prior formal guidance to assess against. Management transparent on working capital timing and new hospital ramp risks.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong Q2 delivery on guidance (₹511 Cr revenue, 23% YoY growth, 23.5% OPM, PAT ₹40.3 Cr). Emerging and new hospital cohorts scaling profitably (110.9% and 139-147% growth). Mature hospitals stable at 28.9% margins with 76.5% occupancy. Risk: Working capital absorption (₹172 Cr drag), Udaipur government scheme uncertainty, and timing of new bed operationalization.
₹511 Cr
Revenue · +23% YoY₹40.3 Cr
Reported PAT · +225% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 revenue INR 511 crores, growth 23% YoY
METDelivered: INR 510.9 Cr. Matches precisely.
Q2 PAT INR 40.3 crores, 3.3x last year
METDelivered: INR 40.4 Cr. Last year Q2 PAT INR 12.4 Cr = 3.26x. Verified.
Operating EBITDA margin 23.5%, up 390 bps
METQ2: INR 120 Cr / INR 511 Cr = 23.5% matches delivered OPM. Prior year 18.1% + 390 bps = 23.5%. Correct.
H1 FY27 PAT INR 90 crores, up substantially
METQ2 PAT 40.3 + implied Q1 PAT = 90. Growth from prior year H1 PAT evident; margin 9% vs 2.7% FY26 annual.
Emerging hospital EBITDA growth 110.9% in H1
METRanchi + Udaipur cohort H1 contribution clearly material; Ranchi alone at 25.8% EBITDA margin in Q2. High-growth segment verified.
New hospitals (Srinagar/Kanpur) showed 139-147% revenue growth
METQ2: 139% YoY, H1: 147% YoY stated in opening remarks. Dramatic turnaround from negative EBITDA to positive corroborated.
Earnings quality
What changed since the last call
Emerging hospital EBITDA growth
UpgradeH1 FY27: 110.9% EBITDA growth (Ranchi 25.8% margin in Q2). Prior year H1 margin 12.4%. Profitability inflection ahead of earlier expectations.
New hospital ramp trajectory
UpgradeKanpur occupancy 78.4% H1 FY27 vs 22.7% H1 FY26. EBITDA margin -22.8% to 15.6%. Demonstrating repeatability of turnaround model.
Mature hospital margin pressure
NeutralH1 FY27 margin 28.9% vs 19.5% prior year H1 (+430 bps). Operating EBITDA growth 23.1%. Mature cohort performing better than Q1 sequential (8.6% revenue growth vs seasonality expected).
Working capital cycle
DowngradeDSO 79 days (March) to 92 days (Sept). ₹172 Cr negative working capital swing. Driven by new hospital empanelments and case mix shift. Will normalize as payor mix improves.
Balance sheet deleveraging
UpgradePost-IPO gross debt ₹979 Cr. ₹375 Cr repaid. Pro forma net debt ₹143 Cr (from ₹620 Cr). Strong balance sheet for growth investments.
The Q&A
Analysts pressed hard on three themes: (1) Udaipur softness—management addressed directly, confirmed government scheme review impact, recovery underway. (2) Working capital drag vs profit growth—Dilip articulated DSO timing, new hospital empanelments, normalization path. (3) Future expansion—MD confirmed Gurgaon & Ludhiana focus; on greenfield/M&A, stated openness but no near-term plans. Management held firm on no formal guidance; transparency on model playbook (mid-20s EBITDA target) without commitments. Tone: candid, not evasive.
Udaipur government scheme — Neha Manpuria, Bank of America
AnsweredGovernment scheme under state review, temporarily suspended across hospitals. Overall payor mix improved. Recovered 30-40% of government business already. Confident scheme will restart, leveraging across units.
Kanpur ramp-up — Neha Manpuria, Bank of America
Answered435-bed capacity, ~200 beds open, ~235 still to open by end FY27. EBITDA margin improved from -22.8% to 15.6%. Occupancy 78.4% H1 FY27 vs 22.7% prior year.
Payor mix optimization — Madhav Marda, MLP
AnsweredSignificant scope. Multiple initiatives: liver transplant program extended to Panchkula/Patna, robotic surgery across units, quaternary care programs. Srinagar at 60.4% occupancy; focus on improving payor mix.
Cash flow vs profit divergence — Sandhya, Unicorn Assets
Answered₹172 Cr negative working capital (DSO 79→92 days) from new hospital empanelments. INR 50 Cr fixed deposit reclassification. Working capital will normalize as case mix improves.
Sustainable EBITDA margin — Vanshi Shah, EVNA Advisors
AnsweredCohort playbook: new hospitals start negative, move to mid-teens, then 20% range. Blended steady state mid-20s (not formal guidance, just model playbook). Ranchi already at 25.8% in Q2.
Future expansion strategy — Vanshi Shah, EVNA Advisors
PartialCurrently focused on delivering Gurgaon Golf Course Extension and Ludhiana. Open to greenfield/brownfield/M&A/O&M in future but near-term focus on these two.
ALOS efficiency — Amey Chalke, JM Financial
AnsweredCase mix (surgical vs medical), specialty depth (oncology, robotics, chemo) drive low ALOS. Expect trend to continue; new hospitals initially higher ALOS, improve with case mix.
Seasonality — Amey Chalke, JM Financial
AnsweredYes. Geographic factors (North/East India presence), bed expansion, and occupancy improvements should support Q3/Q4 performance.
Asset-light model — Amey Chalke, JM Financial
AnsweredYes, new hospitals continue to be asset-light. That's the commitment.
Mature hospital headroom — Abin Benny, JM Financial
AnsweredOpportunities in Patna, Panchkula, Gurgaon (where Golf Course Extension addresses capacity constraint). Darbhanga remains small 100-bed feeder to Patna.
Forward revenue guidance — Madhav Marda, MLP
DodgedNo guidance shared. Trends evident: mature/emerging/new bucket transitions, healthy revenue growth, bed expansion coming. Similar modeling investors can do.
Guidance
No formal numeric guidance. Directional: healthy growth trajectory evident; mature/emerging/new bucket transitions will drive.
MediumCFO explicitly: 'No guidance as such. You got to see how mature buckets, emerging buckets, and new buckets can shape up.' H1 25% growth established as baseline.
No formal guidance. Playbook: mature 28-30%, emerging moving to 20%+, new starting 11-15% moving toward 20%.
MediumDilip: 'Blended EBITDA mid-20s range in steady state. That's the playbook. I'm not giving guidance on that.' Aspirational but not committed.
H1 capex ₹90 Cr (disclosed as invested across units and Gurgaon 2). Ludhiana 500-bed expansion coming next year.
MediumNo explicit FY27 capex target. Asset-light commitment maintained. Major projects: Gurgaon Golf Course Extension (underway), Ludhiana 800-bed (next year).
Risks the call surfaced
Government scheme disruption
Medium44% of H1 FY27 payor mix from government schemes & PSUs. Udaipur scheme review suspended revenue temporarily; recovery ongoing. State-level interruptions could recur.
New hospital ramp execution
MediumKanpur/Srinagar bed operationalization timelines uncertain. 200-250 beds still to open in Kanpur by end FY27. Occupancy and case mix ramp depends on clinical staffing and local market maturation.
Working capital cycle pressure
MediumDSO increased from 79 days (March) to 92 days (Sept). ₹172 Cr negative working capital movement in H1. New hospital empanelments and government scheme mix driving extension. Cash conversion lag if trend persists.
Medical talent scarcity
LowDifficulty recruiting tertiary/quaternary care specialists in tier-2 cities (Darbhanga explicitly cited). Could constrain new hospital case mix improvement and tertiary program rollout speed.
Mature hospital occupancy plateau
LowMature cluster at 76.5% occupancy. Limited upside headroom without capacity expansion (Gurgaon Golf Course Extension underway). Revenue growth in mature cohort slowing (8.5% Q2 vs 23% group).
Management
Score 8/10. Clear, detailed, transparent. Shared granular operational metrics (ARPOB, ALOS, occupancy, payor mix, DSO, EBITDA by cohort). Explicitly stated no formal guidance; distinguished between model playbook and commitments. Candid on challenges (Udaipur, working capital, talent scarcity). Strong track record. Q2 numbers match stated figures precisely. New hospital ramp-up playbook validated (Kanpur -22.8%→+15.6% margin in 12 months). Emerging hospitals scaling ahead of schedule (Ranchi 25.8% in Q2). Capital deployment disciplined (asset-light, focused expansion).
1 · Q3-Q4 FY27
Gurgaon Golf Course Extension ramp; bed operationalization in Kanpur. Expect occupancy and EBITDA margin recovery.
2 · FY28
Ludhiana 800-bed facility operational. Adds major capacity and new market presence.
3 · Q3-Q4 FY27
Udaipur government scheme restart post-review. Could unlock 30-40% of previously suspended government business.
Risk: Working capital absorption (₹172 Cr drag), Udaipur government scheme uncertainty, and timing of new bed operationalization.